Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
The Journal of Haemophilia Practice
Volume 9 (2022): Issue 1 (January 2022)
Open Access
The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model
Declan Noone
Declan Noone
,
Jan Astermark
Jan Astermark
,
Brian O'Mahony
Brian O'Mahony
,
Flora Peyvandi
Flora Peyvandi
,
Kate Khair
Kate Khair
,
Luke Pembroke
Luke Pembroke
and
Kathryn Jenner
Kathryn Jenner
| Jan 03, 2023
The Journal of Haemophilia Practice
Volume 9 (2022): Issue 1 (January 2022)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Clinical Practice
Published Online:
Jan 03, 2023
Page range:
156 - 166
DOI:
https://doi.org/10.2478/jhp-2022-0021
Keywords
Haemophilia
,
Gene therapy
,
Hub and spoke care model
,
Patient-centred care
,
Decision making
,
Follow-up
© 2022 Declan Noone et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
The patient journey in haemophilia gene therapy is complex and multifaceted, presenting challenges to the hub and spoke model of care. Understanding these from the patient viewpoint will help ensure people with haemophilia receive the information, guidance and support they need throughout their gene therapy journey.
Figure 1
Initial engagementPwH may seek information on gene therapy from a variety of sources, including their treatment centres. Both hub and spoke clinicians must be able to provide enough clear, accessible information to enable a good general understanding of gene therapy.
Figure 2
EligibilityWhen establishing eligibility for gene therapy, a blood sample will be taken from the patient to check for antibodies to the AAV vector, and liver and cardiac health. This can be a challenging and potentially stressful time for PwH but enables decisions around future treatment.
Figure 3
Detailed educationIn depth education is key to ensuring that individual PwH are able to make an informed decision about whether or not to have gene therapy. Hub and spoke centres must both be prepared to answer clinical questions; structured information on discussions should be shared between hub and spoke. This step should be considered alongside that for ‘Informed Decision’ (Figure 5).
Figure 4
Core information needed by people with haemophilia before making an informed decision on gene therapy. Where the information provided is text-based, this must be available in the local language.
Figure 5
Informed DecisionThe process of informed decision-making should centre on enabling PwH to weigh up the benefits and risks of gene therapy. This should be supported by both hub and spoke, with information on discussions shared between them. Conversations with peers who have had gene therapy can be helpful as part of the education that supports this informed decision-making. This step should be considered alongside that for ‘Detailed Education’ (Figures 3 and 4).
Figure 6
DosingThe patient must be sure of their choice to have gene therapy. Dosing will take place at the hub, with the ultimate goal being the instigation of factor expression. Communication between the hub and spoke centres on dosing and plans for monitoring and follow-up is essential.
Figure 7
Follow-up Year 1Follow-up in the first year post-dosing is intensive and focused on the individual's response to gene therapy (factor expression, liver). Additional medications may be required to support factor expression (steroids/immunosuppressants). Coordination between hub and spoke is essential.
Figure 8
Follow-up Year 2The intensity of follow-up reduces. Liaison between hub and spoke continues, and the individual will be adapting to post-gene therapy life. A clear and defined treatment plan should be in place for the patient to cover any decrease in factor expression, accidents or surgery.
Figure 9
Follow-up Beyond Year 2Follow-up should usually be regular six-monthly clinic visits. Monitoring of factor expression and liver health will continue, and the hub may request a liver biopsy. Data collected will enable greater understanding and support development of gene therapies going forward. The goal is for the patient to live well post-gene therapy, whatever their individual outcome.
Figure 10
Map of the patient haemophilia gene therapy journeyVisualisation of the key stages of the haemophilia gene therapy journey, focused on the needs of the patient. The journey is complex and the map identifies common elements in the considerations, processes and challenges for PwH and the hub and spoke centres involved in delivering gene therapy and follow-up.
Preview